Obesity has reached epidemic proportions globally, with over 400 million clinically obese patients worldwide. The prevalence of obesity in the US adult population doubled to 25% between 1990 and 2006 and childhood obesity has more than tripled in the last 30 years. In 2008, the Center of Disease Control estimated that obesity related medical costs were $147bn per annum.

Surgical therapy is the only long-term effective treatment; however, it is invasive, expensive and associated with a high long-term failure rate. About 25m Americans qualify for bariatric surgery, yet only 220,000 bariatric surgeries were performed in 2009.

There is an unmet clinical need for a less invasive, non anatomy-altering procedure that is safe and yet can deliver significant weight loss.

Vysera’s Endoscopic Obesity Device (“EOD”) is an endoscopically delivered biomimetic valve, which acts to delay gastric emptying and reduce absorption thus increasing satiety and inducing weight loss.